KR20200032738A - 가변 및 불변 도메인 사이의 엘보우 영역에 기능성 도메인을 갖는 항체 - Google Patents

가변 및 불변 도메인 사이의 엘보우 영역에 기능성 도메인을 갖는 항체 Download PDF

Info

Publication number
KR20200032738A
KR20200032738A KR1020207006050A KR20207006050A KR20200032738A KR 20200032738 A KR20200032738 A KR 20200032738A KR 1020207006050 A KR1020207006050 A KR 1020207006050A KR 20207006050 A KR20207006050 A KR 20207006050A KR 20200032738 A KR20200032738 A KR 20200032738A
Authority
KR
South Korea
Prior art keywords
antibody
domain
antigen
polypeptide chain
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020207006050A
Other languages
English (en)
Korean (ko)
Inventor
안토니오 란차베키아
루카 피코리
Original Assignee
인스티튜트 포 리서치 인 바이오메드슨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인스티튜트 포 리서치 인 바이오메드슨 filed Critical 인스티튜트 포 리서치 인 바이오메드슨
Publication of KR20200032738A publication Critical patent/KR20200032738A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243Colony Stimulating Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018Orthomyxoviridae, e.g. influenza virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027Paramyxoviridae, e.g. respiratory syncytial virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/10Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207006050A 2017-07-31 2018-07-30 가변 및 불변 도메인 사이의 엘보우 영역에 기능성 도메인을 갖는 항체 Pending KR20200032738A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/069357 2017-07-31
PCT/EP2017/069357 WO2019024979A1 (en) 2017-07-31 2017-07-31 FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
PCT/EP2018/070640 WO2019025391A1 (en) 2017-07-31 2018-07-30 ANTIBODIES HAVING FUNCTIONAL DOMAINS IN THE ELBOW REGION BETWEEN A VARIABLE DOMAIN AND A CONSTANT DOMAIN

Publications (1)

Publication Number Publication Date
KR20200032738A true KR20200032738A (ko) 2020-03-26

Family

ID=59626578

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207006050A Pending KR20200032738A (ko) 2017-07-31 2018-07-30 가변 및 불변 도메인 사이의 엘보우 영역에 기능성 도메인을 갖는 항체

Country Status (13)

Country Link
US (1) US12331108B2 (enExample)
EP (1) EP3661962A1 (enExample)
JP (2) JP7297734B2 (enExample)
KR (1) KR20200032738A (enExample)
CN (1) CN111094341A (enExample)
AU (1) AU2018311032B2 (enExample)
BR (1) BR112019028180A2 (enExample)
CA (1) CA3069265A1 (enExample)
EA (1) EA202090364A1 (enExample)
IL (1) IL272303A (enExample)
MX (1) MX2020001080A (enExample)
SG (1) SG11201911658QA (enExample)
WO (2) WO2019024979A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
BR112020018918A2 (pt) 2018-03-22 2021-01-05 Surface Oncology, Inc. Anticorpos anti-il-27 e usos dos mesmos
AU2019266042B2 (en) * 2018-05-10 2025-08-07 Mirabiologics Inc. Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides
MX2020012895A (es) 2018-05-30 2021-05-27 Inst Res Biomedicine Modificacion de linfocitos b al utilizar citidina desaminasa inducida por activacion endogena.
EP3927728A2 (en) 2019-02-21 2021-12-29 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
EP4100434A1 (en) 2020-02-03 2022-12-14 VIR Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
TWI859420B (zh) 2020-02-26 2024-10-21 美商維爾生物科技股份有限公司 抗sars-cov-2抗體及使用其之方法
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
EP4135846A1 (en) 2020-04-14 2023-02-22 VIR Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
JP2023525039A (ja) 2020-05-08 2023-06-14 ヴィア・バイオテクノロジー・インコーポレイテッド Sars-cov-2に対する抗体
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
CA3180477A1 (en) 2020-06-12 2021-12-16 Elizabeth Alexander Antibody therapies for sars-cov-2 infection
EP4217385A2 (en) 2020-09-28 2023-08-02 VIR Biotechnology, Inc. Antibodies against sars-cov-2
CN112225807B (zh) * 2020-10-30 2021-09-07 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用
JP2023551667A (ja) 2020-11-23 2023-12-12 ヴィア・バイオテクノロジー・インコーポレイテッド 抗-インフルエンザ抗体及びその組合せ
KR20230135569A (ko) 2020-11-23 2023-09-25 비르 바이오테크놀로지, 인코포레이티드 인플루엔자 a 바이러스에 대한 항체
WO2022109309A1 (en) 2020-11-23 2022-05-27 Vir Biotechnology, Inc. Broadly neutralizing antibodies against influenza neuraminidase
WO2022115486A1 (en) 2020-11-25 2022-06-02 Vir Biotechnology, Inc. Antibodies that bind to multiple betacoronaviruses
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
EP4271715A4 (en) * 2020-12-30 2024-11-20 Wuxi Biologics Ireland Limited MULTI-SPECIFIC ANTIGEN-BINDING PROTEINS
CN112877394A (zh) * 2021-01-27 2021-06-01 南京大学 B7-h4+单核细胞型mdsc在制备ins激素治疗疗效预测试剂中的应用
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
WO2022236142A2 (en) * 2021-05-07 2022-11-10 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
AU2022280767A1 (en) 2021-05-24 2024-01-18 Humabs Biomed Sa Engineered polypeptides
WO2023034866A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. Antibody therapies for sars-cov-2 infection in pediatric subjects
WO2023034871A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. High concentration antibody therapies for sars-cov-2 infection
CN114934065A (zh) * 2021-11-25 2022-08-23 浙江理工大学绍兴生物医药研究院有限公司 携带免疫检查点分子tim-3抗体基因的溶瘤腺病毒构建方法和应用
EP4444758A2 (en) 2021-12-10 2024-10-16 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
US20230416406A1 (en) 2022-03-10 2023-12-28 Omeros Corporation Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease
WO2023201256A1 (en) 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
WO2023230448A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Combination immunotherapy for influenza
JP2025522295A (ja) 2022-05-23 2025-07-15 ヒューマブス・バイオメッド・ソシエテ・アノニム インフルエンザノイラミニダーゼに対する広域中和抗体
WO2023245078A1 (en) 2022-06-15 2023-12-21 Humabs Biomed Sa Anti-parvovirus antibodies and uses thereof
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
EP4562034A1 (en) 2022-07-27 2025-06-04 Humabs Biomed SA Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
WO2024112818A1 (en) 2022-11-22 2024-05-30 Humabs Biomed Sa Engineered anti-sars-cov-2 antibodies and uses thereof
WO2024118998A2 (en) 2022-12-01 2024-06-06 Vir Biotechnology, Inc. Engineered anti-sars-cov-2 antibodies and methods of using the same
WO2024215762A1 (en) 2023-04-10 2024-10-17 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
WO2025015321A1 (en) 2023-07-13 2025-01-16 Vir Biotechnology, Inc. Broadly neutralizing antibodies against rsv and mpv paramyxoviruses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001270609A1 (en) * 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
BRPI0811857A2 (pt) 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
EP2626371A1 (en) * 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
ES2525346T3 (es) 2008-10-22 2014-12-22 Institute For Research In Biomedicine Métodos para producir anticuerpos a partir de células plasmáticas
WO2012088290A2 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US20140235476A1 (en) * 2012-12-28 2014-08-21 Abbvie, Inc. Multivalent binding protein compositions and methods for identifying variants of same
HK1216894A1 (zh) * 2012-12-28 2016-12-09 Abbvie Inc. 多價結合蛋白組合物
US9814784B2 (en) 2013-01-03 2017-11-14 Celltrion, Inc. Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same
US10526404B2 (en) * 2015-04-29 2020-01-07 Institute For Research In Biomedicine Multispecific anti GM-CSF antibodies
AU2016277887B2 (en) * 2015-06-18 2022-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunoglobulin single variable domain antibody against RSV prefusion F protein
EA039366B1 (ru) * 2015-06-24 2022-01-19 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
EP3313871A1 (en) 2015-06-26 2018-05-02 Institute for Research in Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
KR20180085800A (ko) * 2015-12-07 2018-07-27 젠코어 인코포레이티드 Cd3 및 psma에 결합하는 이종이합체성 항체
AU2019266042B2 (en) * 2018-05-10 2025-08-07 Mirabiologics Inc. Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides

Also Published As

Publication number Publication date
SG11201911658QA (en) 2020-03-30
AU2018311032A1 (en) 2019-12-05
US12331108B2 (en) 2025-06-17
JP7297734B2 (ja) 2023-06-26
US20200325220A1 (en) 2020-10-15
JP2020528758A (ja) 2020-10-01
WO2019025391A1 (en) 2019-02-07
AU2018311032B2 (en) 2025-01-23
EA202090364A1 (ru) 2020-06-26
IL272303A (en) 2020-03-31
MX2020001080A (es) 2020-08-06
WO2019025391A9 (en) 2020-02-13
JP2023123588A (ja) 2023-09-05
EP3661962A1 (en) 2020-06-10
CN111094341A (zh) 2020-05-01
WO2019024979A1 (en) 2019-02-07
CA3069265A1 (en) 2019-02-07
BR112019028180A2 (pt) 2020-07-07

Similar Documents

Publication Publication Date Title
US12331108B2 (en) Antibodies with functional domains in the elbow region between variable and constant domain
CN114245807B (zh) Flt3l-fc融合蛋白和使用方法
US10927184B2 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
KR20200056980A (ko) 유전자 발현의 조건부 조절을 위한 방법 및 시스템
JP2015513394A (ja) 二重特異性キメラ抗原受容体およびその治療的使用
JP2020188762A (ja) 細胞の細胞質への分子の送達のための構築物
US20210254106A1 (en) Engineering b lymphocytes by utilizing endogenous activation-induced cytidine deaminase
JP2024112828A (ja) 消化管系へのペイロード送達のための、btnl3/8を標的とする構築物
TW202330581A (zh) 含有il-21r突變蛋白之免疫細胞介素
KR20230048059A (ko) 키메라 수용체를 발현하는 세포를 포함하는 의약 조성물
CN115485293A (zh) 用于her2的嵌合抗原受体和其使用方法
EA046243B1 (ru) Антитела с функциональными доменами в области изгиба между вариабельным и константым доменом
JP2023536665A (ja) アダプターポリペプチドおよびその使用方法
HK40029066A (en) Antibodies with functional domains in the elbow region between variable and constant domain
TW202509064A (zh) 靶向干擾素α融合蛋白及使用方法
HK40090466A (zh) 包含表达嵌合受体的细胞的药物组合物
TW202544032A (zh) Her2特異性抗原結合蛋白與細胞素之偶聯物
HK40040001A (en) Engineering b lymphocytes by utilizing endogenous activation-induced cytidine deaminase

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210728

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230417

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20240222

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240902